Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

NCT01693068 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

Interventions

DRUG: Pimasertib
DRUG: Dacarbazine

Sponsor

EMD Serono

Collaborators

[object Object]